Wells Fargo & Company Medi Wound Ltd. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.35 - $9.8 $164,312 - $1.19 Million	121,713 Added 18.07%	795,286 $1.11 Million
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.35 $264,844 - $467,957	199,131 Added 41.97%	673,573 $1.24 Million
Q1 2022 May 16, 2022	BUY	$1.86 - $3.24 $282,282 - $491,718	151,765 Added 47.03%	474,442 $944,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.01 $77,523 - $141,304	35,238 Added 12.26%	322,677 $762,000
Q3 2021 Nov 15, 2021	BUY	$3.34 - $4.63 $69,826 - $96,794	20,906 Added 7.84%	287,439 $960,000
Q2 2021 Aug 16, 2021	BUY	$3.38 - $5.71 $6,138 - $10,369	1,816 Added 0.69%	266,533 $1.02 Million
Q1 2021 May 13, 2021	SELL	$3.77 - $6.05 $1,998 - $3,206	-530 Reduced 0.2%	264,717 $1.42 Million
Q4 2020 Feb 09, 2021	BUY	$3.12 - $4.08 $57,376 - $75,031	18,390 Added 7.45%	265,247 $981,000
Q3 2020 Nov 05, 2020	SELL	$3.09 - $4.14 $41,764 - $55,956	-13,516 Reduced 5.19%	246,857 $928,000
Q2 2020 Aug 13, 2020	BUY	$1.47 - $2.97 $60,250 - $121,731	40,987 Added 18.68%	260,373 $773,000
Q1 2020 May 14, 2020	BUY	$1.57 - $3.1 $344,436 - $680,096	219,386 New	219,386 $345,000

Ticker MDWD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,735,200
Market Cap $683M
Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hosp...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.